BigHat Biosciences, a San Carlos, Calif.-based novel protein therapeutics company and developer of an AI-guided antibody design platform, raised $19m in a Series A funding.
The round was led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. As part of the investment, Andreessen Horowitz General Partner, Vineeta Agarwala, MD, PhD joins BigHat’s Board of Directors.
The company intends to use the new capital to expand the scientific and technical teams, hiring antibody and protein engineers, AI/ML engineers, and computational biologists, further develop the platform, scaling capacity and advancement of its own internal therapeutic programs towards human clinical trials.
Led by Co-founder and CEO Mark DePristo, PhD., Co-founder and Chief Scientific Officer (CSO) Peyton Greenside, PhD., BigHat is developing an AI-guided protein therapeutic design platform that integrates a high-speed antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties.
The company is applying these design capabilities to develop new generations of effective treatments for patients suffering from today’s most challenging diseases.
The company was founded by DePristo and Greenside, along with founding advisor Theresa Tribble, a Harvard University MBA and former Chief Business Officer (CBO) for Everlywell. Liz Schwarzbach, PhD, University of Pennsylvania, recently joined as CBO.